Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy
Abstract Aim Skeletal muscle volume has been reported to be an important factor that determines overall survival (OS) and post‐progression survival (PPS) in patients with hepatocellular carcinoma (HCC). However, the impact of skeletal muscle volume on HCC with Barcelona Clinic Liver Cancer (BCLC) st...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5810 |
| _version_ | 1827259875682418688 |
|---|---|
| author | Issei Saeki Takahiro Yamasaki Yurika Yamauchi Tomokazu Kawaoka Shinsuke Uchikawa Akira Hiramatsu Hiroshi Aikata Kazufumi Kobayashi Takayuki Kondo Sadahisa Ogasawara Tetsuhiro Chiba Reo Kawano Kazuaki Chayama Naoya Kato Taro Takami |
| author_facet | Issei Saeki Takahiro Yamasaki Yurika Yamauchi Tomokazu Kawaoka Shinsuke Uchikawa Akira Hiramatsu Hiroshi Aikata Kazufumi Kobayashi Takayuki Kondo Sadahisa Ogasawara Tetsuhiro Chiba Reo Kawano Kazuaki Chayama Naoya Kato Taro Takami |
| author_sort | Issei Saeki |
| collection | DOAJ |
| description | Abstract Aim Skeletal muscle volume has been reported to be an important factor that determines overall survival (OS) and post‐progression survival (PPS) in patients with hepatocellular carcinoma (HCC). However, the impact of skeletal muscle volume on HCC with Barcelona Clinic Liver Cancer (BCLC) stage B (BCLC‐B) remains unclear. We conducted sub‐analyses of a previous study on BCLC‐B and compared our findings with data on HCC with BCLC stage C (BCLC‐C). Methods We retrospectively enrolled 356 patients with HCC (BCLC‐B, n = 78; and BCLC‐C, n = 278) undergoing sorafenib therapy. Prognostic factors were analyzed using various parameters, including skeletal muscle volume. Muscle volume (MV) depletion was designated as less than the median value of the skeletal muscle index for each gender (cutoff value: 45.0 cm2/m2 for male and 38.0 cm2/m2 for female participants). Results Both OS and PPS showed no significant differences in patients with non‐MV depletion and those with MV depletion in the BCLC‐B group (Median OS [MST] 19.3 vs. 13.5 months [p = 0.348]; median PPS 9.7 vs. 10.8 months [p = 0.578]). In the BCLC‐C group, patients with non‐MV depletion had a significantly longer OS and PPS compared to patients with MV depletion (MST 12.4 vs. 9.0 months [p = 0.001] and median PPS 7.9 vs. 5.4 months [p = 0.002]). Multivariate analysis revealed that MV depletion was an independent prognostic factor of OS and PPS in the BCLC‐C group but not in the BCLC‐B group. Conclusions Skeletal muscle volume showed little impact on the clinical outcomes of patients with BCLC‐B undergoing sorafenib therapy. |
| first_indexed | 2024-03-13T08:56:07Z |
| format | Article |
| id | doaj.art-264ad3bdf8c3415999ff96b985e4fa87 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2025-03-22T02:33:32Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-264ad3bdf8c3415999ff96b985e4fa872024-05-04T06:40:57ZengWileyCancer Medicine2045-76342023-05-01129106251063510.1002/cam4.5810Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapyIssei Saeki0Takahiro Yamasaki1Yurika Yamauchi2Tomokazu Kawaoka3Shinsuke Uchikawa4Akira Hiramatsu5Hiroshi Aikata6Kazufumi Kobayashi7Takayuki Kondo8Sadahisa Ogasawara9Tetsuhiro Chiba10Reo Kawano11Kazuaki Chayama12Naoya Kato13Taro Takami14Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Yamaguchi JapanDepartment of Oncology and Laboratory Yamaguchi University Graduate School of Medicine Yamaguchi JapanDepartment of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Yamaguchi JapanDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanNational Center for Geriatrics and Gerontology Innovation Center for Translational Research Aichi JapanCollaborative Research Laboratory of Medical Innovation, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Yamaguchi JapanAbstract Aim Skeletal muscle volume has been reported to be an important factor that determines overall survival (OS) and post‐progression survival (PPS) in patients with hepatocellular carcinoma (HCC). However, the impact of skeletal muscle volume on HCC with Barcelona Clinic Liver Cancer (BCLC) stage B (BCLC‐B) remains unclear. We conducted sub‐analyses of a previous study on BCLC‐B and compared our findings with data on HCC with BCLC stage C (BCLC‐C). Methods We retrospectively enrolled 356 patients with HCC (BCLC‐B, n = 78; and BCLC‐C, n = 278) undergoing sorafenib therapy. Prognostic factors were analyzed using various parameters, including skeletal muscle volume. Muscle volume (MV) depletion was designated as less than the median value of the skeletal muscle index for each gender (cutoff value: 45.0 cm2/m2 for male and 38.0 cm2/m2 for female participants). Results Both OS and PPS showed no significant differences in patients with non‐MV depletion and those with MV depletion in the BCLC‐B group (Median OS [MST] 19.3 vs. 13.5 months [p = 0.348]; median PPS 9.7 vs. 10.8 months [p = 0.578]). In the BCLC‐C group, patients with non‐MV depletion had a significantly longer OS and PPS compared to patients with MV depletion (MST 12.4 vs. 9.0 months [p = 0.001] and median PPS 7.9 vs. 5.4 months [p = 0.002]). Multivariate analysis revealed that MV depletion was an independent prognostic factor of OS and PPS in the BCLC‐C group but not in the BCLC‐B group. Conclusions Skeletal muscle volume showed little impact on the clinical outcomes of patients with BCLC‐B undergoing sorafenib therapy.https://doi.org/10.1002/cam4.5810BCLC stage‐Bhepatocellular carcinomaskeletal musclesorafenib |
| spellingShingle | Issei Saeki Takahiro Yamasaki Yurika Yamauchi Tomokazu Kawaoka Shinsuke Uchikawa Akira Hiramatsu Hiroshi Aikata Kazufumi Kobayashi Takayuki Kondo Sadahisa Ogasawara Tetsuhiro Chiba Reo Kawano Kazuaki Chayama Naoya Kato Taro Takami Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy Cancer Medicine BCLC stage‐B hepatocellular carcinoma skeletal muscle sorafenib |
| title | Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy |
| title_full | Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy |
| title_fullStr | Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy |
| title_full_unstemmed | Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy |
| title_short | Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy |
| title_sort | impact of skeletal muscle volume on patients with bclc stage b hepatocellular carcinoma undergoing sorafenib therapy |
| topic | BCLC stage‐B hepatocellular carcinoma skeletal muscle sorafenib |
| url | https://doi.org/10.1002/cam4.5810 |
| work_keys_str_mv | AT isseisaeki impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT takahiroyamasaki impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT yurikayamauchi impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT tomokazukawaoka impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT shinsukeuchikawa impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT akirahiramatsu impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT hiroshiaikata impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT kazufumikobayashi impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT takayukikondo impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT sadahisaogasawara impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT tetsuhirochiba impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT reokawano impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT kazuakichayama impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT naoyakato impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy AT tarotakami impactofskeletalmusclevolumeonpatientswithbclcstagebhepatocellularcarcinomaundergoingsorafenibtherapy |